MYGN - Myriad Genetics, Inc.
| Previous Close | 25.08 |
| Open | 25.17 |
| Bid | 22.61 x 800 |
| Ask | 29.30 x 900 |
| Day's Range | 24.44 - 25.60 |
| 52 Week Range | 22.07 - 50.44 |
| Volume | 1,064,248 |
| Avg. Volume | 1,434,961 |
| Market Cap | 1.809B |
| Beta (3Y Monthly) | 1.40 |
| PE Ratio (TTM) | 408.17 |
| EPS (TTM) | 0.06 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.70 |
- Business Wire
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Myriad Genetics, Inc. – MYGN
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Myriad Genetics, Inc. resulting from allegations that Myriad may have issued materially misleading business information to the investing public.
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Myriad Genetics, Inc. - MYGN
Pomerantz LLP is investigating claims on behalf of investors of Myriad Genetics, Inc. (“Myriad” or the “Company”) (MYGN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On August 13, 2019, after market-close, Myriad reported its Fiscal Fourth-Quarter and Full-Year 2019 Financial Results.
- PR Newswire
Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm
SAN FRANCISCO, Aug. 19, 2019 /PRNewswire/ -- Hagens Berman notifies investors in Myriad Genetics, Inc. (MYGN) of the firm's investigation of possible disclosure violations concerning its GeneSight® Psychotropic test, one of Myriad's most important products.
- Thomson Reuters StreetEvents
Edited Transcript of MYGN earnings conference call or presentation 13-Aug-19 8:30pm GMT
Q4 2019 Myriad Genetics Inc Earnings Call
- Benzinga
Barron's Picks And Pans: American Eagle Outfitters, Chevron, Grocery Outlet And More
The cover story in this weekend's Barron's offers stock picks for an energy sector rebound. Other featured articles discuss how the trade war is hitting tech's bottom line and why banks are not an alternative ...
- Barrons.com
Myriad Genetics Stock Has an F.D.A. Issue
A test that Myriad is counting on to restore sales growth is in trouble with the U.S. Food and Drug Administration.
- PR Newswire
Investor Alert: Kaplan Fox Investigates Myriad Genetics, Inc.
NEW YORK , Aug. 16, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has been investigating claims on behalf of investors who purchased shares of Myriad Genetics, Inc. ("Myriad" ...
- Motley Fool
Myriad Genetics Limps Into Fiscal 2020
A sluggish end to fiscal 2019 and weaker-than-expected guidance for the year ahead aren't instilling much confidence in investors.
- Simply Wall St.
Myriad Genetics (NASDAQ:MYGN) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Motley Fool
Why Myriad Genetics, Nordstrom, and Luckin Coffee Slumped Today
Different challenges hit these companies but led to the same result.
- Investor's Business Daily
Why This Genetic-Testing Outlet Just Wiped Out Its 26% Breakout Gain
Myriad Genetics stock crashed Wednesday after the genetic-testing outlet unveiled new reimbursement challenges, dampening its 2020 outlook. Shares wiped out their gains after a breakout.
- Motley Fool
Here's Why Myriad Genetics Is Getting Crushed Today
The genetic testing company reported fiscal 2019 operating results and told investors that regulators want changes to an important product.
- MarketWatch
Myriad Genetics stock plummets 39% after lower-than-expected earnings, FDA questions
Shares of molecular-diagnostics firm Myriad Genetics Inc. plummeted 39% Wednesday morning after the company reported lower-than-expected fourth-quarter earnings and disclosed that the U.S. Food and Drug Administration had requested changes to one of its tests. On Tuesday afternoon, Myriad reported a fourth-quarter loss of $4.2 million, or 6 cents a share, after reporting earnings of $14.5 million, or 20 cents a share, in the year-earlier quarter. Adjusted EPS for the latest quarter was 41 cents a share, below the FactSet consensus of 47 cents a share. Revenue fell 11% to $215.4 million, missing the FactSet consensus of $221.6 million and the company's previous fourth-quarter guidance of $220 million. "Unfortunately, revenue in the fourth quarter was two percent below expectations largely due to lower reimbursement for our expanded carrier screening test," said Myriad CEO Mark Capone in a statement. Myriad said in its 10-K that the FDA had requested changes to its GeneSight test. The company said it has submitted a proposal they believe addresses the FDA's principal concerns. The GeneSight test is meant to analyze how a patient's genes may affect their response to depression drugs. UnitedHealth said in August that it would cover the test for members, sending Myriad's stock soaring. Shares of Myriad have now fallen 7.2% so far this year, while the S&P 500 has gained 14.9%.
- Zacks
Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up
Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.
- Barrons.com
Myriad Genetics Stock Craters on Weak Earnings and FDA Scrutiny
Shares of the molecular-diagnostic biotech firm were down 30.4% after the company reported financial results that missed expectations and it said the FDA had “requested changes” to GeneSight.
- Motley Fool
What You'll Want to Know About Myriad Genetics' Disappointing Q4 Results
There wasn't much to like with the molecular diagnostics company's latest quarterly update.
- TheStreet.com
Myriad Genetics Sinks on Fourth-Quarter Earnings and Revenue Miss
Myriad Genetics tumbles after missing Wall Street's fiscal fourth-quarter earnings and revenue expectations.
Motley FoolMyriad Genetics Inc (MYGN) Q4 2019 Earnings Call Transcript
MYGN earnings call for the period ending June 30, 2019.
- Zacks
Myriad Genetics (MYGN) Lags Q4 Earnings and Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -12.77% and -2.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Investor's Business Daily
Will This Medical Stock Sacrifice Its Breakout On A Wide Quarterly Miss?
Myriad Genetics stock plunged late Tuesday after the genetic testing outfit lagged Wall Street's quarterly forecasts and issued light guidance for 2020. The stock recently broke out.
- GlobeNewswire
Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results
Total Fourth-Quarter Revenues of $215.4 MillionFourth-Quarter Diluted EPS of ($0.06) and Adjusted EPS of $0.41 SALT LAKE CITY, Aug. 13, 2019 -- Myriad Genetics, Inc. (NASDAQ:.
- Benzinga
Myriad Genetics Q4 Earnings Preview
Myriad Genetics (NASDAQ: MYGN ) announces its next round of earnings this Tuesday, August 13. Here's Benzinga's look at Myriad Genetics's Q4 earnings report. Earnings and Revenue Based on Myriad Genetics ...
- Zacks
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?
Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.
- Zacks
What's in the Offing for Cisco Systems' (CSCO) Q4 Earnings?
Cisco (CSCO) is benefiting from its expanding footprint in the rapidly growing security market. Also, partnerships and synergies from acquisitions will boost the company's revenue base.
